Register for an Event

FRIDAY, DECEMBER 8, 2017

CME Breakfast Symposium
7:00 AM – 11:00 AM

Georgia World Congress Center
Room B401-B402
285 Andrew Young International Blvd NW
Atlanta, GA 30313

PROGRAM AGENDA

7:00 AM Registration and Breakfast

7:40 AM LLS Overview

Lee Greenberger, PhD
Chief Scientific Officer, LLS

7:45 AM Welcome

Steven T. Rosen, MD, FACP, FASCO

7:50 AM Precision Medicine/Technology Overview

Karen L. Kaul, MD, PhD

8:10 AM Clonal Evolution and Targeted Therapies: Deciphering the Future of Myeloma Therapy

Jonathan J. Keats, PhD

8:30 AM Precision Medicine in B Cell Lymphoma

Sandeep Dave, MD, MS

8:50 AM Precision Medicine in T Cell Lymphoma

Wing C. (John) Chan, MD

9:10 AM A New Era in Acute Myeloid Leukemia (AML)/Acute Lymphoblastic Leukemia (ALL)

Cheryl L. Willman, MD

9:30 AM Applying Precision Therapy to Clinical Practice

Anas Younes, MD

9:50 AM Panel Discussion and Q&A

Steven T. Rosen, MD, FACP, FASCO; Wing C. (John) Chan, MD; Sandeep Dave, MD, MS; Karen L. Kaul, MD, PhD; Jonathan J. Keats, PhD; Cheryl L. Willman, MD; Anas Younes, MD

11:00 AM Adjourn

FACULTY

Steven T. Rosen, MD, FACP, FASCO
Provost & Chief Scientific Officer
Director, Comprehensive Cancer Center and Beckman Research Institute
Irell & Manella Cancer Center Director's Distinguished Chair
City of Hope Medical Center
Duarte, CA

Wing C. (John) Chan, MD
Professor and Vice Chairman for Research, Department of Pathology
Co-Leader, Hematological Malignancies Program
City of Hope Medical Center
Duarte, CA

Sandeep Dave, MD, MS
Professor of Medicine
Director of Cancer Genetics and Genomics Program
Duke Cancer Institute
Durham, NC

Karen L. Kaul, MD, PhD
Chair, Department of Pathology and Laboratory Medicine
Duckworth Family Chair
NorthShore University HealthSystem
Evanston, IL
Clinical Professor of Pathology
University of Chicago Pritzker School of Medicine
Chicago, IL

Jonathan J. Keats, PhD
Assistant Professor & Director of Bioinformatics
Integrated Cancer Genomics
Translational Genomics Research Institute (TGen)
Phoenix, AZ

Cheryl L. Willman, MD
The Maurice and Marguerite Liberman Distinguished Endowed
Chair in Cancer Research
UNM Distinguished Professor of Pathology, UNM School of Medicine
Director & CEO
University of New Mexico Comprehensive Cancer Center
Albuquerque, NM

Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, NY

TARGET AUDIENCE
This activity is designed for researchers in hematology/oncology and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies. The program will provide the intended audience with cutting edge research about newly approved and emerging treatments for leukemia, lymphoma, and myeloma that can be incorporated into a precision medicine framework to improve outcomes of patients with hematologic malignancies.

EDUCATIONAL OBJECTIVES
After completing this activity, participants should be better able to:

Describe the evolving role of precision medicine in the treatment and management of patients with leukemia, lymphoma, and myeloma

Outline new and emerging treatments for leukemia, lymphoma, and myeloma that can be incorporated into a precision medicine framework through their specific targets and mechanisms of action

Define important factors that currently limit the incorporation of precision medicine into hematology/oncology practice and strategies that can help to overcome these limitations

Implement strategies that optimize the communication and coordination between healthcare professionals who are involved in the provision of precision medicine

Continuing Education Information

Physician Continuing Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, The Leukemia & Lymphoma Society, and RMEI Medical Education LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

FEE INFORMATION
There is no fee for this educational activity.

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact us prior to the live event at (866) 992-9950.

STATEMENT OF SUPPORT
This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education LLC, and Postgraduate Institute for Medicine. Supported by independent educational grants from AbbVie Inc., Amgen, AstraZeneca Pharmaceuticals LP/Acerta Pharma, and Celgene Corporation. Additional funding provided by The Leukemia & Lymphoma Society.

For information on leukemia, lymphoma, or myeloma, contact an LLS Information Specialist at (800) 955-4572 or infocenter@LLS.org , or visit www.LLS.org.

FOLLOW LLS